معرفی
Dr Geoffrey Coxon is a Lecturer in Medicinal Chemistry at the Strathclyde Institute of Pharmacy and Biomedical Sciences (SIPBS), University of Strathclyde. He is a co-founder and Deputy Leader of TB Drug Discovery UK (TBD-UK), a national collaborative network advancing tuberculosis drug research. His work involves close collaboration with scientists, clinicians, and UK policymakers to strengthen the national and global response to TB.
His research interests lie at the intersection of medicinal chemistry and infectious disease, with a primary focus on the discovery and development of novel agents to treat tuberculosis, particularly targeting drug-resistant strains. His work encompasses the synthesis and evaluation of thiacetazone analogues, investigation of resistance mechanisms in Mycobacterium species, and exploration of natural products for bioactive compounds. He also contributes to strategic frameworks for early-stage TB drug discovery.
The recent publications highlight a strong trend in anti-tubercular drug development, with an emphasis on understanding resistance mechanisms and designing effective chemical entities. His work spans synthetic organic chemistry, pharmacological evaluation, and translational research, contributing significantly to the fields of antibiotic resistance and drug discovery. Several publications focus on Mycobacterium tuberculosis and M. abscessus, demonstrating a consistent theme in targeting challenging mycobacterial infections.
- Teaching Excellence Award Recipient (2020)
- Appointed Deputy Leader and Director of Medicinal Chemistry of TBD-UK (2009)
Dr Coxon has been a Principal Investigator and Co-investigator on multiple research projects funded by EPSRC and other bodies, including doctoral training partnerships and the Interacellular Drug Delivery Centre. He supervises research students and is actively involved in current research extending into 2027. His leadership in TBD-UK highlights his role in shaping national research strategy in TB drug development.
He has contributed to professional activities as a keynote speaker at international conferences, including the Gordon Research Conference on TB Drug Development (2009) and the International Symposium on Tuberculosis in India (2008), reflecting his recognition in the global TB research community.
